- Home
- KVUE vs RGC Comparison
KVUE vs RGC Comparison
Compare KVUE & RGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KVUE
- RGC
- Stock Information
- Founded
- KVUE 2022
- RGC 2014
- Country
- KVUE United States
- RGC Hong Kong
- Employees
- KVUE N/A
- RGC N/A
- Industry
- KVUE Specialty Chemicals
- RGC Medicinal Chemicals and Botanical Products
- Sector
- KVUE Consumer Discretionary
- RGC Health Care
- Exchange
- KVUE Nasdaq
- RGC Nasdaq
- Market Cap
- KVUE 39.8B
- RGC 38.6B
- IPO Year
- KVUE 2023
- RGC 2021
- Fundamental
- Price
- KVUE $20.78
- RGC $12.85
- Analyst Decision
- KVUE Buy
- RGC
- Analyst Count
- KVUE 12
- RGC 0
- Target Price
- KVUE $24.38
- RGC N/A
- AVG Volume (30 Days)
- KVUE 15.8M
- RGC 292.2K
- Earning Date
- KVUE 08-07-2025
- RGC 10-24-2025
- Dividend Yield
- KVUE 3.96%
- RGC N/A
- EPS Growth
- KVUE 28.77
- RGC N/A
- EPS
- KVUE 0.74
- RGC N/A
- Revenue
- KVUE $15,141,000,000.00
- RGC N/A
- Revenue This Year
- KVUE $0.09
- RGC N/A
- Revenue Next Year
- KVUE $3.19
- RGC N/A
- P/E Ratio
- KVUE $28.00
- RGC N/A
- Revenue Growth
- KVUE N/A
- RGC N/A
- 52 Week Low
- KVUE $19.75
- RGC $0.09
- 52 Week High
- KVUE $25.17
- RGC $83.60
- Technical
- Relative Strength Index (RSI)
- KVUE 41.90
- RGC 45.58
- Support Level
- KVUE $20.43
- RGC $12.22
- Resistance Level
- KVUE $21.78
- RGC $16.69
- Average True Range (ATR)
- KVUE 0.40
- RGC 0.96
- MACD
- KVUE -0.07
- RGC 0.29
- Stochastic Oscillator
- KVUE 22.95
- RGC 17.93
About KVUE Kenvue Inc.
Kenvue is the world's largest pure-play consumer health company by sales, generating over $15 billion in annual revenue. Formerly known as Johnson & Johnson's consumer segment, Kenvue spun off and went public in May 2023. It operates in a variety of silos within consumer health, such as cough, cold and allergy care, pain management, face and body care, and oral care, as well as women's health. Its portfolio has some of the most well-known brands in the space, including Tylenol, Listerine, Johnson's, Aveeno, and Neutrogena. Despite playing in a fragmented industry with intense competition and changing consumer preferences, many of Kenvue's brands are the global leader in their respective segment thanks to their strong brand power.
About RGC Regencell Bioscience Holdings Limited
Regencell Bioscience Holdings Ltd is a bioscience company focusing on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degenerations, specifically ADHD and ASD, and infectious diseases affecting people's immune systems.